Daiwa-Pharmaceutical Co.
September 13, 2004
1 Min Read
Daiwa-Pharmaceutical Co.
The Fibrinolytic Benefits of NKCP Soy-Natto Powder forCardiovascular Health
TOKYODaiwa Pharmaceuticalwill present information on its latest patented innovation: a totally advancedand unique fibrinolytic soy-natto powderNKCP. The session will includedetails on NKCPs safety and efficacy as a beneficial fibrinolytic soy-nattoextract marketed in Japan for its cardiovascular health benefits.
The VendorWorks presentation will be given Friday, Oct. 1,from 1 to 1:50 p.m. at SupplySide West. For additional information, visitwww.daiwa-pharm.com or Booth #1906-1908 at SupplySide West.
Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
You May Also Like